文献类型： 外文期刊

作者： Yu, D-H ¹ ; Hu, X-D ² ; Cai, H. ¹ ;

作者机构： 1.Peking Univ, Coll Life Sci, Natl Lab Protein Engn & Plant Genet Engn, Beijing 100871, Peoples R China

2.Xinjiang Acad Anim Sci, Inst Vet Med, Urumqi, Peoples R China

关键词： mycobacterium tuberculosis;combined DNA vaccine;immunotherapeutic effect;INH plus PZA

期刊名称：GENE THERAPY （ 影响因子：5.25； 五年影响因子：4.294 ）

ISSN： 0969-7128

年卷期： 2008 年 15 卷 9 期

页码：

收录情况： SCI

摘要： Although most cases of tuberculosis ( TB) can be cured with antibiotics, relapse is common if patients do not continue chemotherapy for at least 6 months. Thus, improved therapeutic strategies are urgently needed. We previously found that the combined DNA vaccine encoding the Mycobacterium tuberculosis proteins Ag85B, MPT- 64 and MPT- 83 protected mice from TB following H37Rv challenge and considered whether this combined DNA vaccine has a therapeutic effect. In the present work, we demonstrate that boosting the efficiency of the immune system with the combined DNA vaccine may be a valuable adjunct to shorten the duration of antibacterial chemotherapy. Mice treated with the combined DNA vaccine along with isoniazid and pyrazinamide showed significantly higher interferon-gamma responses to a mixture of the three specific antigens ( P < 0.001), which were accompanied by a significant reduction in colony-forming unit in H37Rv-infected animals 3-5 months after treatment ( P < 0.001). These results suggest that the combined DNA vaccine along with conventional TB chemotherapy has strong potential for TB immunotherapy and may provide new alternatives to control the disease.